Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Julia Jauch-Lembach

Fri0087 Efficacy, Safety, and Immunogenicity Results of the Switch From Reference Adalimumab (Refadl) to Sandoz Biosimilar Adalimumab (Gp2017, SDZ-Adl) From Admyra Phase 3 Study in Patients With Moderate-To-Severe Rheumatoid Arthritis (Ra)

2019

English

Related publications

Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study

Arthritis Research & Therapy

2019

English

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

2017

English

AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis

2018

English

Safety of Adalimumab Biosimilar MSB11022 (Acetate-Buffered Formulation) in Patients With Moderately-To-Severely Active Rheumatoid Arthritis

Clinical Rheumatology

Medicine

Rheumatology

2019

English

Pms47 - Cost-Effectiveness of Tofacitinib Compared With Adalimumab in the Treatment of Moderate to Severe Rheumatoid Arthritis in Iran

English

Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain

ClinicoEconomics and Outcomes Research

English

Long-Term Safety and Effectiveness of Adalimumab for the Treatment of Japanese Patients With Rheumatoid Arthritis: 3-Year Results From a Postmarketing Surveillance of 552 Patients

English

A Phase III Randomized Study to Evaluate the Efficacy and Safety of CT-P13 Compared With Reference Infliximab in Patients With Active Rheumatoid Arthritis: 54-Week Results From the PLANETRA Study

Arthritis Research & Therapy

2016

English

Efficacy and Safety of Sirukumab in Japanese Patients With Moderate to Severe Rheumatoid Arthritis Inadequately Controlled by Disease Modifying Anti-Rheumatic Drugs: Subgroup Analysis of a Phase 3 Study

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Julia Jauch-Lembach

Fri0087 Efficacy, Safety, and Immunogenicity Results of the Switch From Reference Adalimumab (Refadl) to Sandoz Biosimilar Adalimumab (Gp2017, SDZ-Adl) From Admyra Phase 3 Study in Patients With Moderate-To-Severe Rheumatoid Arthritis (Ra)

Related publications

Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis

Safety of Adalimumab Biosimilar MSB11022 (Acetate-Buffered Formulation) in Patients With Moderately-To-Severely Active Rheumatoid Arthritis

Pms47 - Cost-Effectiveness of Tofacitinib Compared With Adalimumab in the Treatment of Moderate to Severe Rheumatoid Arthritis in Iran

Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain

Long-Term Safety and Effectiveness of Adalimumab for the Treatment of Japanese Patients With Rheumatoid Arthritis: 3-Year Results From a Postmarketing Surveillance of 552 Patients

A Phase III Randomized Study to Evaluate the Efficacy and Safety of CT-P13 Compared With Reference Infliximab in Patients With Active Rheumatoid Arthritis: 54-Week Results From the PLANETRA Study

Efficacy and Safety of Sirukumab in Japanese Patients With Moderate to Severe Rheumatoid Arthritis Inadequately Controlled by Disease Modifying Anti-Rheumatic Drugs: Subgroup Analysis of a Phase 3 Study